Ascendis Pharma A/S (FRA:A71)
Germany
· Delayed Price · Currency is EUR | Market Cap | 10.93B |
| Revenue (ttm) | 646.55M |
| Net Income (ttm) | -232.94M |
| Shares Out | n/a |
| EPS (ttm) | -3.87 |
| PE Ratio | n/a |
| Forward PE | 76.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 8 |
| Open | 171.00 |
| Previous Close | 172.00 |
| Day's Range | 171.00 - 171.00 |
| 52-Week Range | 115.00 - 186.00 |
| Beta | n/a |
| RSI | 43.69 |
| Earnings Date | Feb 11, 2026 |
About Ascendis Pharma
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses o... [Read more]
Financial Performance
In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.
Financial StatementsNews
FDA Extends Review for Ascendis Pharma's (ASND) TransCon CNP
FDA Extends Review for Ascendis Pharma's (ASND) TransCon CNP
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S ‘ (NASDAQ: ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondropla...
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S‘ (NASDAQ: ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasi...
Is the Market Bullish or Bearish on Ascendis Pharma AS?
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has risen 3.68% since its last report. According to exchange reported data, there are now 3.55 million shares sold short , which...
FDA Extends Decision Date For TransCon CNP In Pediatric Achondroplasia
(RTTNews) - Ascendis Pharma A/S (ASND), on Wednesday, reported that the FDA has extended the decision date for TransCon CNP, proposed for the treatment of children with achondroplasia, by three months...
Ascendis Pharma (ASND) Faces FDA Review Extension for TransCon CNP
Ascendis Pharma (ASND) Faces FDA Review Extension for TransCon CNP
US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare genetic disorder that causes dwarfism, the company said.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announ...
Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | ASND Stock News
Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | ASND Stock News
Ascendis Pharma (ASND) Reports Positive Results from TransCon CNP Trial for Achondroplasia
Ascendis Pharma (ASND) Reports Positive Results from TransCon CNP Trial for Achondroplasia
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Tri...
Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansion
Q3 2025 Ascendis Pharma A/S Earnings Call Transcript
Q3 2025 Ascendis Pharma A/S Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsChad FugereJan Mikkelsen - President, CEO, Member of...
Ascendis Pharma GAAP EPS of - €1.00, revenue of €143.1M
Ascendis Pharma Reports Third Quarter 2025 Financial Results
– Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ®
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Ascendis Pharma A/S (NASDAQ: ASND) will release earnings results for the third quarter, after the closing bell on Wednesday, Nov. 12. Analysts expect the Hellerup, Denmark-based company to report a q...
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Ascendis Pharma A/S (NASDAQ:ASND) will release earnings results for the third quarter, after the closing bell on Wednesday, Nov. 12.
A Look Ahead: Ascendis Pharma's Earnings Forecast
Ascendis Pharma (NASDAQ: ASND) is preparing to release its quarterly earnings on Wednesday, 2025-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts...
Ascendis Pharma (ASND) Reports Positive Long-Term Findings for TransCon PTH
Ascendis Pharma (ASND) Reports Positive Long-Term Findings for TransCon PTH
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal fu...
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal fu...
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wedne...
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of uri...
Biotech is back. Here's why these rallying stocks belong in your portfolio now.
The volatile sector is seeing greater stability, and these four stocks can profit.